We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.53 | 0.70% | 76.41 | 76.42 | 76.57 | 76.80 | 75.96 | 76.34 | 4,488,586 | 21:21:02 |
From May 2021 to May 2024
By Jaime Llinares Taboada
AstraZeneca PLC said Thursday that the combination of its Imfinzi immunotherapy with tremelimumab antibodies improved survival in lung cancer patients.
The pharmaceutical company said Imfinzi and tremelimumab with chemotherapy improved overall survival by 23% in 1st-line Stage IV non-small cell lung cancer at a Phase 3 trial.
"Adding a short course of tremelimumab to Imfinzi for those patients already receiving chemotherapy, reduced the risk of cancer progressing or death by 28% compared to chemotherapy alone," said Susan Galbraith, AstraZeneca's executive vice president at Oncology R&D.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
September 09, 2021 11:28 ET (15:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
